ANNUAL REPORT 2008-2009 APPENDIX I

Publications in peer reviewed journals in FY 08-09

1. **Baginsky, P.** Should we treat all patients with coronary heart disease or the equivalent with statins? Current Atherosclerosis Reports 11: 28-35, 2009.


4. Licciardone JC, **Clearfield MB**, Guillory VJ. Clinical Practice Characteristics of Osteopathic and Allopathic Primary Care Physicians at Academic Health Centers: Results from the National Ambulatory Medical Care Survey. Academic Medicine 2009; 84:744-750.


10. **Gugliucci A.** Bastos DH, **Schulze J.** Souza MF. Caffeic and chlorogenic acids in Ilex paraguariensis extracts are the main inhibitors of AGE generation by methylglyoxal in model proteins. Fitoterapia, 2009 80(6). p. 339-44.


14. Yadong Cui, MD, PhD, Douglas J Watson, PhD, Cynthia J. Girman, DrPH, Deborah R. Shapiro, DrPH, Antonio M. Gotto, MD, DPhil, **Hiserote, Patricia DO**, and **Michael B. Clearfield, DO**. Effects of Increasing High-Density Lipoprotein Cholesterol and Decreasing Low-Density Lipoprotein Cholesterol on the Incidence of First Acute Coronary Events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). The American Journal of Cardiology. 2009;104:829-834


17. Barrows, B. Cheung, K. Bialobrzeski, T. Foster, **Schulze J., Miller, A**. Extracellular potassium dependency of block of HERG by quinidine and cisapride is primarily determined by the permeant ion and not by inactivation. Channels (Austin), 2009. 3(4).


Presentations/Abstracts FY 08-09


8. Ricther, K., Barrows, B., Schulze, J., and Miller, A. Activation of the cardiac potassium channel HERG may be a determinant of the extracellular potassium dependency of block of HERG by terfenadine. Presented by Kris Richter (OMSII) at the Leiden Medical Students Association Conference, Leiden, The Netherlands, March 09.

9. Ricther, K., Barrows, B., Hioe, S., Yun, J., Farrell, M., Schulze, J., and Miller, A. Block of the HERG mutant D540K by terfenadine shows the opposite dependency on extracellular potassium compared to block of WT HERG by terfenadine. Presented by A. Miller at the Biophysical Society Meeting, Boston, Ma, March 09.
10. **Puder, Barbara.** "Neuroscience teacher training program for elementary school teachers" American Association of Anatomists annual meeting, New Orleans, LA, April 2009.


22. Keppler, D., Zhang, J., Bihani, T. and Lin, A.W. The cysteine protease inhibitor CST1 is a candidate biomarker of senescent cells. Presented at the 89th Annual Meeting of the American Association for the Advancement of Science (AAAS) - Pacific Division, from June 15 to 20, 2008 in Waimea, Hawaii.


30. Clearfield M. Getting to Goal: Clinical Barriers to Non-Compliance 113th Annual American Osteopathic Association Convention, Las Vegas, Nevada

Books:


Book Chapters:


GRANTS, INTRAMURAL

1. Dr. Nathalie Garcia-Russell and Dr. Peter Baginsky are working on their intramural grants. Drs. Garcia Russell, Ted Wong and OMS II Ben Abo, spearhead a group of several OMM and Primary Care faculty including Drs. Ekholm, Hiserote, Burns and Mokari and several students to work on the putative role of OMT on acute mountain sickness syndrome.

2. Dr Peter Baginsky works on the role or AGE measurement in skin as a predictor of diabetic complications. Both projects involve many students and show TUCOM’s commitment to clinical research, collaborative work and outreach.

GRANTS, EXTRAMURAL

Awarded Now

1. Schwarz, Jean-Marc. Principal Investigator. American Diabetes Association (1/1/08-12/31/2010). Total: $550,000

2. Gochin, Miriam. NS059403-S1 (Principal Investigator) 8/1/2008-2/21/2010 (Supplement) Application of HIV-1 fusion inhibitor assay at MLSCN, project approval April 2, 2009 ($25,000 direct).

Awarded Ongoing

1. Schwarz, Jean-Marc. Principal Investigator. NIH/NIDDK 1R01DK078133-01A1 (9/1/07-8/31/2011). Total: $1.2 Million

2. Schwarz, Jean-Marc. Role: Co-Investigator; (PI: Grunfeld) NIH/NIDDK R01 DK66999 (3/1/04-12/31/2012).

Submitted Pending

2. **Gochin, Miriam.** R21-NS066469 (Principal Investigator) Assay development for high affinity non-peptide HIV-1 gp41 inhibitors, Resubmitted 3/20/09, Score: 144 (waiting for council review), $125,000 direct costs.

3. **Elul, Tamira.** NIH R15, Morphogenesis of optic axons in the developing visual system, $150,000, Submitted Feb. 2009

4. **Hermel, Evan.** Co-PI, Grand Challenges/Explorations Grant (Direct costs $100,000) Gates Foundation H. Michael Ellerby, Co-PI. Touro University-CA, Vallejo, CA.

5. **Hermel, Evan.** Co-PI, RC1, Novel Drugs to Permit the Safe Use of Heterologous Passive Immunization for Malarial and Other Infectious Diseases. (Direct plus indirect $768,000). NIH. H. Michael Ellerby, Co-PI. Touro University-CA, Vallejo, CA.


7. **Schwarz, Jean-Marc.** NIDDK challenge grant Title: Pediatric fructose restriction: reversing co-morbidity PI: Lustig (UCSF) and Schwarz (Touro-CA) Submitted 4/2009. Total: $1 Million


Submitted Unfunded

1. **Hermel, Evan.** Co-PI, Induction of Broad-Spectrum Immunity. (Direct costs $100,000). Gates Foundation Grand Challenges/Explorations grant. Karl Meszaros, Co-PI.


Awarded-Student Grant

APPENDIX II: PRODUCTIVITY IN PAST 5 YEARS

**COM PUBLICATIONS IN PEER REVIEWED JOURNALS**

![Bar chart showing publications in peer-reviewed journals from 2004 to 2008.]

**COM PRESENTATIONS/ABSTRACTS**

![Bar chart showing presentations/abstracts from 2004 to 2008.]

Annual Report Research, August 2009